CD8A and neoplasm: Therefore, the use of tumor‐reactive CD8+ cytotoxic T lymphocytes (CTL) requires efficient in vitro approaches allowing not only the expansion of CTLs to large numbers but improvement and preservation of cytotoxicity to achieve a significant tumor removal or reduction.